UTHR Q1 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379M+6.4% YoY

Gross Profit

$356M93.9% margin

Operating Income

-$65M-17.1% margin

Net Income

$28M7.5% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

-1.5%

Cash Flow

Operating Cash Flow

$90M

Free Cash Flow

$79M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.2B

Stockholders' Equity

$3.4B

Cash & Equivalents

$832M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379M	$356M	+6.4%
Gross Profit	$356M	$333M	+7.0%
Operating Income	-$65M	$167M	-138.9%
Net Income	$28M	$138M	-79.4%

Revenue Segments

Remodulin

$130M34%

Tyvaso

$123M32%

Orenitram

$72M19%

Unituxin

$44M12%

Adcirca

$10M3%

Geographic Segments

UNITED STATES

$354M93%

European Union And Others

$25M7%